My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 138

    1.

    Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants.

    Hopley C, Salkeld G, Wang JJ, Mitchell P.

    Br J Ophthalmol. 2004 Apr;88(4):450-4.PMID: 15031152 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.

    Hopley C, Salkeld G, Mitchell P.

    Br J Ophthalmol. 2004 Aug;88(8):982-7.PMID: 15258009 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.

    Karnon J, Czoski-Murray C, Smith K, Brand C, Chakravarthy U, Davis S, Bansback N, Beverley C, Bird A, Harding S, Chisholm I, Yang YC.

    Health Technol Assess. 2008 Jun;12(27):iii-iv, ix-124.PMID: 18513468 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Cost-effectiveness of vitamin therapy for age-related macular degeneration.

    Rein DB, Saaddine JB, Wittenborn JS, Wirth KE, Hoerger TJ, Narayan KM, Clemons T, Sorensen SW.

    Ophthalmology. 2007 Jul;114(7):1319-26. Epub 2007 Feb 22.PMID: 17320962 [PubMed - indexed for MEDLINE]Related articles

    5.

    Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.

    Earnshaw SR, Moride Y, Rochon S.

    Clin Ther. 2007 Sep;29(9):2096-106; discussion 2094-5.PMID: 18035208 [PubMed - indexed for MEDLINE]Related articles

    6.

    Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.

    Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.

    Pharmacoeconomics. 2007;25(10):863-79.PMID: 17887807 [PubMed - indexed for MEDLINE]Related articles

    7.

    Model study of AREDS antioxidant supplementation of AMD compared to Visudyne: a dominant strategy?

    Trevithick J, Massel D, Robertson JM, Tomany S, Wall R.

    Ophthalmic Epidemiol. 2004 Dec;11(5):337-46.PMID: 15590581 [PubMed - indexed for MEDLINE]Related articles

    8.

    Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.

    Manser R, Dalton A, Carter R, Byrnes G, Elwood M, Campbell DA.

    Lung Cancer. 2005 May;48(2):171-85. Epub 2005 Jan 4.PMID: 15829317 [PubMed - indexed for MEDLINE]Related articles

    9.

    The cost-effectiveness of testing for hepatitis C in former injecting drug users.

    Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, Stein K.

    Health Technol Assess. 2006 Sep;10(32):iii-iv, ix-xii, 1-93.PMID: 16948891 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Screening for proteinuria in US adults: a cost-effectiveness analysis.

    Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR.

    JAMA. 2003 Dec 17;290(23):3101-14.PMID: 14679273 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data.

    Brown GC, Brown MM, Campanella J, Beauchamp GR.

    Am J Ophthalmol. 2005 Oct;140(4):679-87.PMID: 16226519 [PubMed - indexed for MEDLINE]Related articles

    12.

    [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration]

    Neubauer AS, Holz FG, Schrader W, Back EI, Kühn T, Hirneiss C, Kampik A.

    Klin Monbl Augenheilkd. 2007 Sep;224(9):727-32. German. PMID: 17846963 [PubMed - indexed for MEDLINE]Related articles

    13.

    The burden of age-related macular degeneration.

    Schmier JK, Jones ML, Halpern MT.

    Pharmacoeconomics. 2006;24(4):319-34. Review.PMID: 16605279 [PubMed - indexed for MEDLINE]Related articles

    14.

    The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

    Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

    Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.PMID: 17999840 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4-5 years: a systematic review and economic evaluation.

    Carlton J, Karnon J, Czoski-Murray C, Smith KJ, Marr J.

    Health Technol Assess. 2008 Jun;12(25):iii, xi-194. Review.PMID: 18513466 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case.

    Smith DH, Fenn P, Drummond M.

    Br J Ophthalmol. 2004 Sep;88(9):1107-12.PMID: 15317697 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    The cost-effectiveness of screening for oral cancer in primary care.

    Speight PM, Palmer S, Moles DR, Downer MC, Smith DH, Henriksson M, Augustovski F.

    Health Technol Assess. 2006 Apr;10(14):1-144, iii-iv. Review.PMID: 16707071 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Visual screening for malignant melanoma: a cost-effectiveness analysis.

    Losina E, Walensky RP, Geller A, Beddingfield FC 3rd, Wolf LL, Gilchrest BA, Freedberg KA.

    Arch Dermatol. 2007 Jan;143(1):21-8.PMID: 17224538 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

    Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

    Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.PMID: 16545208 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).

    Kobelt G, Andlin-Sobocki P, Brophy S, Jönsson L, Calin A, Braun J.

    Rheumatology (Oxford). 2004 Sep;43(9):1158-66. Epub 2004 Jun 29.PMID: 15226514 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity